Bone 192, 117383
After the insurer joined others in restricting access to GLP-1 drugs, Point32Healths operating income rebounded to $86 million in the first quarter of 2026 from a loss of $39 million in the same period of 2025
REWARDS CLUB EARN UP TO 5% CASHBACK ALL YOUR BEAUTY FAVOURITES30K+ products, 700+ brands REWARDS CLUBup to 5% cashback on all purchases LOYALTY PROGRAMSexclusive by brand REFER A FRIENDwin 5 BeautyEdits K-Beauty Offers Natural& vegan PremiumCosmetics HaircarePro BeautyTech PetCare DermApproved ClinicalBeauty HealthSupplements Daily Balance Beauty Advisors Tuesday, July 28 -20% discount Wednesday, July 29 Thursday, July 30 ZMW 580.14 ZMW 967.03 ZMW 12115.39 ZMW 509.42 ZMW 636.83 ZMW 1128.78 ZMW 1254.35 ZMW 98.15 ZMW 245.67 ZMW 483.21 ZMW 508.61 ZMW 532.38 ZMW 760.58 ZMW 80.26 ZMW 267.61 Sweet Awards | July 2026 How to Apply Sunscreen Correctly ZMW 159.92 ZMW 200.15 ZMW 232.66 ZMW 358.04 ZMW 208.89 ZMW 318.21 ZMW 104.65 ZMW 348.89 ZMW 1797.91 ZMW 2247.39 ZMW 329.18 ZMW 439.12 Explore 4.9/5 Over 800,000 users all over the world trust SweetCare
Central Nervous System Effects The primary mechanism driving incretin-mediated weight reduction occurs in the brain
Tirzepatide, a GLP-1 and GIP receptor agonist originally developed for type 2 diabetes, has shown promise in clinical trials for improving both glycemic control and weight loss, two factors that directly impact neuropathic progression
However, growing research suggests that GLP-1 medications may influence things like reward processing and impulse control
